Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

  • In development
  • GID-TA11279
  • Expected publication date: 

Documents

Documents created during the development process.

Declaration of interests

Draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6256